Cargando…

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

Approximately 90% of alpha-synuclein (α-Synuclein) deposited in Lewy bodies is phosphorylated at serine 129 suggesting that the accumulation of phosphorylated α-Synuclein is critical in the pathogenesis of Parkinson’s disease. However, in vivo experiments addressing the role of phosphorylated α-Synu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karampetsou, Mantia, Ardah, Mustafa T., Semitekolou, Maria, Polissidis, Alexia, Samiotaki, Martina, Kalomoiri, Maria, Majbour, Nour, Xanthou, Georgina, El-Agnaf, Omar M. A., Vekrellis, Kostas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705684/ https://www.ncbi.nlm.nih.gov/pubmed/29184069 http://dx.doi.org/10.1038/s41598-017-15813-8

Ejemplares similares

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Intrastriatal Administration of Exosome-Associated Pathological Alpha-Synuclein Is Not Sufficient by Itself to Cause Pathology Transmission
por: Karampetsou, Mantia, et al.
Publicado: (2020)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
por: Ardah, Mustafa T., et al.
Publicado: (2020)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Targeting NLRP3 Inflammasome Activation in Severe Asthma
por: Theofani, Efthymia, et al.
Publicado: (2019)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis
por: Ouzounoglou, Eleftherios, et al.
Publicado: (2014)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease
por: Leandrou, Emmanouela, et al.
Publicado: (2019)

Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
por: Skavatsou, Eleni, et al.
Publicado: (2021)

Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation
por: Oueslati, Abid, et al.
Publicado: (2014)

Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy
por: Xilouri, Maria, et al.
Publicado: (2009)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species
por: Pampalakis, Georgios, et al.
Publicado: (2016)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Circulating Conventional and Plasmacytoid Dendritic Cell Subsets Display Distinct Kinetics during In Vivo Repeated Allergen Skin Challenges in Atopic Subjects
por: Vittorakis, Stelios, et al.
Publicado: (2014)

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
por: Wu, Jia-Zhen, et al.
Publicado: (2019)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Oliveira, Luis M. A., et al.
Publicado: (2021)

Activin-A is up-regulated in severe asthma, attenuates allergic responses and is associated with angiogenesis
por: Samitas, Konstantinos, et al.
Publicado: (2013)

The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease
por: Kapaki, Elisabeth, et al.
Publicado: (2013)

Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma
por: Emmanouilidou, Evangelia, et al.
Publicado: (2011)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease
por: Semitekolou, Maria, et al.
Publicado: (2009)

Activin-A impedes the establishment of CD4(+) T cell exhaustion and enhances anti-tumor immunity in the lung
por: Morianos, Ioannis, et al.
Publicado: (2021)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Phosphorylation induces distinct alpha-synuclein strain formation
por: Ma, Meng-Rong, et al.
Publicado: (2016)

Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption
por: Pediaditakis, Iosif, et al.
Publicado: (2021)

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
por: Van Rompuy, Anne-Sophie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l5d04shu8kqki6r6841c4cr8si